Galmed says Aramchol oral film boosts bioavailability 150%, CNS exposure 300% in Parkinson’s program - GLMD News | RalliesGalmed says Aramchol oral film boosts bioavailability 150%, CNS exposure 300% in Parkinson’s program
G
GLMD• Aramchol oral film data in Parkinson’s program
- Galmed advanced Aramchol for Parkinson’s disease with an orally dispersible film formulation designed for buccal and sublingual absorption.
- Development data showed about 150% higher systemic bioavailability versus conventional oral dosing.
- CNS exposure increased about 300%, supporting a brain-targeted delivery strategy for its SCD1 inhibitor.
- The program is positioned as a potential out-licensing candidate targeting a $6+ billion Parkinson’s therapeutics market.
